Therapeutic targeting of tumor suppressor genes

Cancer

Volumn 121, Issue 9, 2015, Pages 1357-1368

  Morris, Luc G T ^a   Chan, Timothy A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

cancer; oncogene; therapeutic targeting; tumor suppressor gene

Indexed keywords

B RAF KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CANCER VACCINE; DNA METHYLTRANSFERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE DEACETYLASE INHIBITOR; ISOCITRATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLYCOMB GROUP PROTEIN; PROTEIN KINASE B INHIBITOR; PROTEIN MDM2; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; SIRTUIN; ANTINEOPLASTIC AGENT; TP53 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DNA END JOINING REPAIR; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HISTONE METHYLATION; HOMOLOGOUS RECOMBINATION; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE; VIRAL GENE THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC EPIGENESIS; GENETICS; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA REPAIR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84928242556     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29140     Document Type: Review

References (117)

1. Knudson AG Jr,. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68: 820-823.
2. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986; 323: 643-646.
3. Nowell PC,. The clonal evolution of tumor cell populations. Science. 1976; 194: 23-28.
4. DeMars R, Held KR,. The spontaneous azaguanine-resistant mutants of diploid human fibroblasts. Humangenetik. 1972; 16: 87-110.
5. Seshadri R, Kutlaca RJ, Trainor K, Matthews C, Morley AA,. Mutation rate of normal and malignant human lymphocytes. Cancer Res. 1987; 47: 407-409.
6. Quon KC, Berns A,. Haplo-insufficiency? Let me count the ways. Genes Dev. 2001; 15: 2917-2921.
7. Cook WD, McCaw BJ,. Accommodating haploinsufficient tumor suppressor genes in Knudson's model. Oncogene. 2000; 19: 3434-3438.
8. Kinzler KW, Vogelstein B,. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 1997; 386: 761, 763.
9. Vogelstein B, Kinzler KW,. Cancer genes and the pathways they control. Nat Med. 2004; 10: 789-799.
10. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW,. Cancer genome landscapes. Science. 2013; 339: 1546-1558.
11. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013; 3: 2650.
12. Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013; 45: 1134-1140.
13. Freed-Pastor WA, Prives C,. Mutant p53: one name, many proteins. Genes Dev. 2012; 26: 1268-1286.
14. Hollstein M, Sidransky D, Vogelstein B, Harris CC,. p53 mutations in human cancers. Science. 1991; 253: 49-53.
15. Levine AJ, Momand J, Finlay CA,. The p53 tumour suppressor gene. Nature. 1991; 351: 453-456.
16. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401-404.
17. Michalovitz D, Halevy O, Oren M,. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 1990; 62: 671-680.
18. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119: 861-872.
19. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI,. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006; 443: 214-217.
20. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445: 656-660.
21. Kenzelmann Broz D, Attardi LD,. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis. 2010; 31: 1311-1318.
22. Wang Y, Suh YA, Fuller MY, et al. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011; 121: 893-904.
23. Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008; 13: 454-463.
24. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009; 69: 510-517.
25. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303: 844-848.
26. Khoo KH, Verma CS, Lane DP,. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014; 13: 217-236.
27. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274: 948-953.
28. Chene P, Fuchs J, Bohn J, Garcia-Echeverria C, Furet P, Fabbro D,. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J Mol Biol. 2000; 299: 245-253.
29. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008; 105: 3933-3938.
30. Michaelis M, Rothweiler F, Barth S, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011; 2: e243.
31. Wang S, Sun W, Zhao Y, et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014; 74: 5855-5865.
32. Lehmann S, Bykov VJ, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012; 30: 3633-3639.
33. Schuler M, Rochlitz C, Horowitz JA, et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther. 1998; 9: 2075-2082.
34. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999; 91: 763-771.
35. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH,. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997; 3: 639-645.
36. Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002; 62: 5736-5742.
37. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000; 6: 879-885.
38. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000; 60: 6359-6366.
39. Mehta SA, Christopherson KW, Bhat-Nakshatri P, et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene. 2007; 26: 3329-3337.
40. Weissmueller S, Manchado E, Saborowski M, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell. 2014; 157: 382-394.
41. Leffers N, Lambeck AJ, Gooden MJ, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer. 2009; 125: 2104-2113.
42. Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI,. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010; 10: 983-991.
43. Schuler PJ, Harasymczuk M, Visus C, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014; 20: 2433-2444.
44. Keniry M, Parsons R,. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008; 27: 5477-5485.
45. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997; 57: 5221-5225.
46. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci U S A. 1998; 95: 13513-13518.
47. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95: 29-39.
48. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91: 231-241.
49. Manning BD, Cantley LC,. AKT/PKB signaling: navigating downstream. Cell. 2007; 129: 1261-1274.
50. Potter CJ, Pedraza LG, Xu T,. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002; 4: 658-665.
51. Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005; 7: 193-204.
52. Vivanco I, Sawyers CL,. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2: 489-501.
53. Courtney KD, Corcoran RB, Engelman JA,. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010; 28: 1075-1083.
54. Workman P, Clarke PA, Raynaud FI, van Montfort RL,. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010; 70: 2146-2157.
55. Haruta T, Uno T, Kawahara J, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000; 14: 783-794.
56. Chandarlapaty S, Sawai A, Scaltriti M, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011; 19: 58-71.
57. Tao JJ, Castel P, Radosevic-Robin N, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014; 7: ra29.
58. Ciccia A, Elledge SJ,. The DNA damage response: making it safe to play with knives. Mol Cell. 2010; 40: 179-204.
59. Lieber MR,. The mechanism of human nonhomologous DNA end joining. J Biol Chem. 2008; 283: 1-5.
60. Robertson AB, Klungland A, Rognes T, Leiros I,. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci. 2009; 66: 981-993.
61. Li GM,. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008; 18: 85-98.
62. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434: 913-917.
63. Vodenicharov MD, Sallmann FR, Satoh MS, Poirier GG,. Base excision repair is efficient in cells lacking poly(ADP-ribose) polymerase 1. Nucleic Acids Res. 2000; 28: 3887-3896.
64. Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS,. Appraising iniparib, the PARP inhibitor that never was-what must we learn? Nat Rev Clin Oncol. 2013; 10: 688-696.
65. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011; 364: 205-214.
66. Shall S, Gaymes T, Farzaneh F, Curtin N, Mufti GJ,. The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients. Methods Mol Biol. 2011; 780: 239-266.
67. Gupta A, Yang Q, Pandita RK, et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle. 2009; 8: 2198-2210.
68. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
69. Rodriguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010; 123: 189-196.
70. Turner N, Tutt A, Ashworth A,. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004; 4: 814-819.
71. Lee MN, Tseng RC, Hsu HS, et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res. 2007; 13: 832-838.
72. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010; 116: 4578-4587.
73. Morrison A, Johnson AL, Johnston LH, Sugino A,. Pathway correcting DNA replication errors in Saccharomyces cerevisiae. EMBO J. 1993; 12: 1467-1473.
74. Martin SA, McCabe N, Mullarkey M, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell. 2010; 17: 235-248.
75. Jiang H, Reinhardt HC, Bartkova J, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009; 23: 1895-1909.
76. Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 2006; 66: 5354-5362.
77. Mizuarai S, Yamanaka K, Itadani H, et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer. 2009; 8: 34.
78. De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, Wurdinger T,. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res. 2011; 17: 4200-4207.
79. Costanzo M, Baryshnikova A, Bellay J, et al. The genetic landscape of a cell. Science. 2010; 327: 425-431.
80. Laufer C, Fischer B, Billmann M, Huber W, Boutros M,. Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. Nat Methods. 2013; 10: 427-431.
81. Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A,. Searching for synthetic lethality in cancer. Curr Opin Genet Dev. 2011; 21: 34-41.
82. Jerby-Arnon L, Pfetzer N, Waldman YY, et al. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell. 2014; 158: 1199-1209.
83. Muller FL, Colla S, Aquilanti E, et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012; 488: 337-342.
84. Bignell GR, Greenman CD, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010; 463: 893-898.
85. You JS, Jones PA,. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012; 22: 9-20.
86. Baylin SB, Jones PA,. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer. 2011; 11: 726-734.
87. Hatziapostolou M, Iliopoulos D,. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci. 2011; 68: 1681-1702.
88. Esteller M,. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007; 8: 286-298.
89. Schepers A, Clevers H,. Wnt signaling, stem cells, and cancer of the gastrointestinal tract. Cold Spring Harb Perspect Biol. 2012; 4: a007989.
90. Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012; 22: 271-282.
91. Issa JP,. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004; 4: 988-993.
92. Fang F, Turcan S, Rimner A, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med. 2011; 3: 75ra25.
93. Kanai Y, Ushijima S, Nakanishi Y, Sakamoto M, Hirohashi S,. Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers. Cancer Lett. 2003; 192: 75-82.
94. Yamashita Y, Yuan J, Suetake I, et al. Array-based genomic resequencing of human leukemia. Oncogene. 2010; 29: 3723-3731.
95. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363: 2424-2433.
96. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10: 223-232.
97. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014; 124: 2705-2712.
98. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483: 479-483.
99. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012; 483: 474-478.
100. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340: 626-630.
101. Lu C, Venneti S, Akalin A, et al. Induction of sarcomas by mutant IDH2. Genes Dev. 2013; 27: 1986-1998.
102. Borodovsky A, Salmasi V, Turcan S, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013; 4: 1737-1747.
103. Turcan S, Fabius AW, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget. 2013; 4: 1729-1736.
104. Ocker M, Schneider-Stock R,. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol. 2007; 39: 1367-1374.
105. West AC, Johnstone RW,. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124: 30-39.
106. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C,. Cancer genetics of epigenetic genes. Hum Mol Genet. 2007; 16 (spec no 1): R28-R49.
107. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109: 31-39.
108. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27: 5410-5417.
109. Mills AA,. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer. 2010; 10: 669-682.
110. Chase A, Cross NC,. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011; 17: 2613-2618.
111. Ezhkova E, Pasolli HA, Parker JS, et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell. 2009; 136: 1122-1135.
112. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007; 21: 1050-1063.
113. Kim W, Bird GH, Neff T, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013; 9: 643-650.
114. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-133.
115. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2454.
116. Rajasagi M, Shukla SA, Fritsch EF, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014; 124: 453-462.
117. Wang H, Han H, Mousses S, Von Hoff DD,. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Semin Oncol. 2006; 33: 513-520.